Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.

Steinbach WJ, Roilides E, Berman D, Hoffman JA, Groll AH, Bin-Hussain I, Palazzi DL, Castagnola E, Halasa N, Velegraki A, Dvorak CC, Charkabarti A, Sung L, Danziger-Isakov L, Lachenauer C, Arrieta A, Knapp K, Abzug MJ, Ziebold C, Lehrnbecher T, Klingspor L, Warris A, Leckerman K, Martling T, Walsh TJ, Benjamin DK Jr, Zaoutis TE; International Pediatric Fungal Network..

Pediatr Infect Dis J. 2012 Dec;31(12):1252-7. doi: 10.1097/INF.0b013e3182737427.

PMID:
22982980
2.

Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.

Cornely OA, Vazquez J, De Waele J, Betts R, Rotstein C, Nucci M, Pappas PG, Ullmann AJ.

Mycoses. 2014 Feb;57(2):79-89. doi: 10.1111/myc.12104.

PMID:
23786573
3.

Invasive candidiasis in Pakistan: clinical characteristics, species distribution and antifungal susceptibility.

Farooqi JQ, Jabeen K, Saeed N, Iqbal N, Malik B, Lockhart SR, Zafar A, Brandt ME, Hasan R.

J Med Microbiol. 2013 Feb;62(Pt 2):259-68. doi: 10.1099/jmm.0.048785-0.

5.

Epidemiology of candidaemia and invasive candidiasis. A changing face.

Quindós G.

Rev Iberoam Micol. 2014 Jan-Mar;31(1):42-8. doi: 10.1016/j.riam.2013.10.001. Review.

PMID:
24270071
6.

Candida speciation, antifungal treatment and adverse events in pediatric invasive candidiasis: results from 441 infections in a prospective, multi-national study.

Palazzi DL, Arrieta A, Castagnola E, Halasa N, Hubbard S, Brozovich AA, Fisher BT, Steinbach WJ.

Pediatr Infect Dis J. 2014 Dec;33(12):1294-6. doi: 10.1097/INF.0000000000000431.

PMID:
24892850
7.

Echinocandin use in the neonatal intensive care unit.

Caudle KE, Inger AG, Butler DR, Rogers PD.

Ann Pharmacother. 2012 Jan;46(1):108-16. doi: 10.1345/aph.1Q346. Review.

PMID:
22190252
8.

Neonatal invasive candidiasis in Tunisian hospital: incidence, risk factors, distribution of species and antifungal susceptibility.

Ben Abdeljelil J, Saghrouni F, Nouri S, Geith S, Khammari I, Fathallah A, Sboui H, Ben Saïd M.

Mycoses. 2012 Nov;55(6):493-500. doi: 10.1111/j.1439-0507.2012.02189.x.

PMID:
22448706
9.

Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.

Pfaller MA, Andes DR, Diekema DJ, Horn DL, Reboli AC, Rotstein C, Franks B, Azie NE.

PLoS One. 2014 Jul 3;9(7):e101510. doi: 10.1371/journal.pone.0101510.

10.

Sentinel surveillance of invasive candidiasis in Spain: epidemiology and antifungal susceptibility.

Nieto MC, Tellería O, Cisterna R.

Diagn Microbiol Infect Dis. 2015 Jan;81(1):34-40. doi: 10.1016/j.diagmicrobio.2014.05.021.

PMID:
25439581
11.

Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial.

Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll AH, Arrieta A; Micafungin Invasive Candidiasis Study Group..

Pediatr Infect Dis J. 2008 Sep;27(9):820-6. doi: 10.1097/INF.0b013e31817275e6.

PMID:
18679151
12.

Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey.

Pemán J, Cantón E, Quindós G, Eraso E, Alcoba J, Guinea J, Merino P, Ruiz-Pérez-de-Pipaon MT, Pérez-del-Molino L, Linares-Sicilia MJ, Marco F, García J, Roselló EM, Gómez-G-de-la-Pedrosa E, Borrell N, Porras A, Yagüe G; FUNGEMYCA Study Group..

J Antimicrob Chemother. 2012 May;67(5):1181-7. doi: 10.1093/jac/dks019.

PMID:
22351683
13.

Association of clinical and demographic factors in invasive candidiasis caused by fluconazole-resistant Candida species: a study in 15 hospitals, Medellín, Colombia 2010-2011.

Maldonado NA, Cano LE, De Bedout C, Arbeláez CA, Roncancio G, Tabares AM, Robledo CG, Robledo J; Grupo GERMEN..

Diagn Microbiol Infect Dis. 2014 Jun;79(2):280-6. doi: 10.1016/j.diagmicrobio.2014.02.003.

PMID:
24666706
14.

Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.

Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM.

Clin Infect Dis. 2009 Jun 15;48(12):1695-703. doi: 10.1086/599039.

PMID:
19441981
15.

Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009).

Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):278-83. doi: 10.1016/j.diagmicrobio.2010.06.015.

PMID:
20846808
16.

[Micafungin for the treatment of neonatal invasive candidiasis].

Infante-López ME, Rojo-Conejo P.

Rev Iberoam Micol. 2009 Mar 31;26(1):56-61. doi: 10.1016/S1130-1406(09)70009-9. Review. Spanish.

17.

In vitro antifungal susceptibilities of Candida isolates from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia.

Amran F, Aziz MN, Ibrahim HM, Atiqah NH, Parameswari S, Hafiza MR, Ifwat M.

J Med Microbiol. 2011 Sep;60(Pt 9):1312-6. doi: 10.1099/jmm.0.027631-0.

PMID:
21459913
18.

Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates.

Roilides E, Farmaki E, Evdoridou J, Dotis J, Hatziioannidis E, Tsivitanidou M, Bibashi E, Filioti I, Sofianou D, Gil-Lamaignere C, Mueller FM, Kremenopoulos G.

Eur J Clin Microbiol Infect Dis. 2004 Oct;23(10):745-50.

PMID:
15605181
19.

Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O; AmarCand Study Group..

Crit Care Med. 2009 May;37(5):1612-8. doi: 10.1097/CCM.0b013e31819efac0.

PMID:
19325476
20.

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH, Lau W, Facklam D, Buell DN.

Eur J Clin Microbiol Infect Dis. 2005 Oct;24(10):654-61. Erratum in: Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):69.

PMID:
16261306
Items per page

Supplemental Content

Support Center